aibioX4 Pharmaceuticals announces restructuring and workforce reduction of 43 employees, about 30%
Tickers XFOR
X4 will close its Vienna facility and pause preclinical programs to focus on mavorixafor in chronic neutropenia. It expects annual spending to fall by $30-35 million and believes its funds will last into the first half of 2026.
Key facts
- Company
- X4 Pharmaceuticals, Inc. (NASDAQ: XFOR)
- News type
- Distress
- Primary source
- X4 Pharmaceuticals, Inc Form 8-K filed February 6, 2025 (SEC EDGAR)
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) announced a strategic restructuring on February 6, 2025 that includes a net reduction of 43 employees, about 30% of its workforce. The company disclosed the plan in a Form 8-K under Item 2.05, which covers costs tied to exit or disposal activities. X4 expects the shift to cut annual spending by $30 million to $35 million, and it believes its funds will support operations into the first half of 2026.
What the restructuring includes
X4 describes the plan as a restructuring of its workforce and capital spending. The aim is to focus on advancing mavorixafor for chronic neutropenia while optimizing its U.S. promotion of XOLREMDI. The filing lists five steps: discontinuing research efforts, closing the company's facility in Vienna, Austria, pausing preclinical drug candidate programs, scaling the U.S. commercial field team and supporting roles, and streamlining other spending to support clinical development of mavorixafor in the larger chronic neutropenia population.
The company expects the workforce reduction to be substantially complete in the first quarter of 2025.
Costs and savings
X4 estimates charges of about $3.0 million for severance and other employee termination costs, mostly in the first quarter of 2025. It expects the change in focus to cut annual spending by $30 million to $35 million. The filing says the cost estimates, the spending reduction and their timing rest on assumptions, and that actual results may differ. It also says the company may incur costs it has not yet contemplated.
The forward-looking statements list the risks. The restructuring may cost more or take longer than expected, or may fail to achieve its intended results. The cost of the planned activities may also be higher than expected, which could lead X4 to use cash faster or to change or cut back some plans.
The company and its lead drug
The annual report for the fiscal year ended December 31, 2023 describes X4 as a late clinical-stage biopharmaceutical company developing treatments for rare diseases tied to immune system dysfunction. Its lead candidate, mavorixafor, is a small-molecule selective antagonist of the CXCR4 chemokine receptor, developed as an oral, once-daily therapy. The XOLREMDI name in the 8-K refers to the product the company already promotes in the United States.
That report shows a net loss of $101.2 million for 2023. Net cash used in operating activities was $96.5 million for the same year, and net cash from financing activities was $88.5 million. Those figures set the scale of the cuts. A $30 million to $35 million reduction in annual spending is large against $96.5 million of operating cash burn in 2023, but the 8-K does not show what the remaining run rate will be.
Runway and the first half of 2026
The 8-K says X4 believes it will have sufficient funds to support operations into the first half of 2026. The filing does not say what cash balance that estimate is based on. It also does not say how much of the savings depends on closing the Vienna site, or whether the company plans to raise money before the runway ends.
The filing gives no date for a financing or a strategic decision. The filing does not say which data or partner milestones the company needs to reach before that period ends.